Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone.

IF 1.7

Human psychopharmacology Pub Date : 2014-01-01 Epub Date: 2013-11-25 DOI:10.1002/hup.2366

Siti Norsyuhada Roffeei, Gavin P Reynolds, Nor Zuraida Zainal, Mas Ayu Said, Ahmad Hatim, Syarinaz Ahmad Aida, Zahurin Mohamed

{"title":"Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone.","authors":"Siti Norsyuhada Roffeei, Gavin P Reynolds, Nor Zuraida Zainal, Mas Ayu Said, Ahmad Hatim, Syarinaz Ahmad Aida, Zahurin Mohamed","doi":"10.1002/hup.2366","DOIUrl":null,"url":null,"abstract":"Objectives: Various genetic polymorphisms have been reported to be associated with antipsychotic-induced weight gain. In this study, we aimed to determine whether risk polymorphisms in 12 candidate genes are associated with reduction in body mass index (BMI) of patients following switching of antipsychotics to aripiprazole or ziprasidone.Methods: We recruited 115 schizophrenia patients with metabolic abnormalities and who have been on at least 1 year treatment with other antipsychotics; they were then switched to either aripiprazole or ziprasidone. They were genotyped, and their BMI monitored for 6 months.Results: Significant associations with reduction in BMI at 6 months following switching were found in two of these genes: with rs1800544 of the ADRA2A gene (CC + CG [-0.32 ± 1.41 kg/m²] vs GG [-1.04 ± 1.63 kg/m²], p = 0.013) and with rs1801131 of the MTHFR gene (AA [-0.36 ± 1.53] vs AC + CC [-1.07 ± 1.53], p = 0.015).Conclusion: The study data indicated that carriage of the ADRA2A rs1800544 GG genotype and the MTHFR rs1801131 C allele are associated with BMI reduction in this population following switching of antipsychotics to aripiprazole and ziprasidone.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"38-45"},"PeriodicalIF":1.7000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hup.2366","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hup.2366","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/11/25 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 13

Abstract

Objectives: Various genetic polymorphisms have been reported to be associated with antipsychotic-induced weight gain. In this study, we aimed to determine whether risk polymorphisms in 12 candidate genes are associated with reduction in body mass index (BMI) of patients following switching of antipsychotics to aripiprazole or ziprasidone.

Methods: We recruited 115 schizophrenia patients with metabolic abnormalities and who have been on at least 1 year treatment with other antipsychotics; they were then switched to either aripiprazole or ziprasidone. They were genotyped, and their BMI monitored for 6 months.

Results: Significant associations with reduction in BMI at 6 months following switching were found in two of these genes: with rs1800544 of the ADRA2A gene (CC + CG [-0.32 ± 1.41 kg/m²] vs GG [-1.04 ± 1.63 kg/m²], p = 0.013) and with rs1801131 of the MTHFR gene (AA [-0.36 ± 1.53] vs AC + CC [-1.07 ± 1.53], p = 0.015).

Conclusion: The study data indicated that carriage of the ADRA2A rs1800544 GG genotype and the MTHFR rs1801131 C allele are associated with BMI reduction in this population following switching of antipsychotics to aripiprazole and ziprasidone.

查看原文本刊更多论文

ADRA2A和MTHFR基因多态性与改用阿立哌唑或齐拉西酮后体重减轻的关系

目的:各种遗传多态性已被报道与抗精神病药物引起的体重增加有关。在这项研究中，我们旨在确定12个候选基因的风险多态性是否与抗精神病药物改用阿立哌唑或齐拉西酮后患者体重指数(BMI)的降低有关。方法:我们招募了115例患有代谢异常且接受其他抗精神病药物治疗至少1年的精神分裂症患者;然后他们被换成阿立哌唑或齐拉西酮。对他们进行了基因分型，并对他们的BMI进行了6个月的监测。结果:其中两个基因与转换后6个月BMI降低有显著相关性:ADRA2A基因rs1800544 (CC + CG[-0.32±1.41 kg/m²]vs GG[-1.04±1.63 kg/m²]，p = 0.013)和MTHFR基因rs1801131 (AA[-0.36±1.53]vs AC + CC[-1.07±1.53]，p = 0.015)。结论:研究数据表明，ADRA2A rs1800544 GG基因型和MTHFR rs1801131 C等位基因的携带与该人群在抗精神病药物转换为阿立哌唑和齐拉西酮后的BMI降低有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human psychopharmacology

自引率

0.00%

发文量